Clearmind Medicine Receivables 2023-2025 | CMND

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clearmind Medicine receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clearmind Medicine receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$95B
Zoetis (ZTS)	$66.3B
Takeda Pharmaceutical (TAK)	$46.8B
Daiichi Sankyo, - (DSNKY)	$41.7B
Summit Therapeutics (SMMT)	$18.2B
Sandoz Group AG (SDZNY)	$17.7B
Merck (MKKGY)	$17.2B
Astellas Pharma (ALPMY)	$16.9B
Shionogi (SGIOY)	$14.1B
United Therapeutics (UTHR)	$12.8B
Neurocrine Biosciences (NBIX)	$10B
IPSEN (IPSEY)	$8.6B
Orion OYJ (ORINY)	$8B
Madrigal Pharmaceuticals (MDGL)	$6.7B
Stevanato Group S.p.A (STVN)	$6.6B
Corcept Therapeutics (CORT)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.8B
Ono Pharmaceutical (OPHLF)	$5.5B
Grifols, S.A (GRFS)	$4.9B
Ionis Pharmaceuticals (IONS)	$4.5B
Soleno Therapeutics (SLNO)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.3B
Recursion Pharmaceuticals (RXRX)	$2.2B
Hypermarcas (HYPMY)	$2.1B
NewAmsterdam Pharma (NAMS)	$1.8B
Centessa Pharmaceuticals (CNTA)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B